source
- FDA approves Rasonque, first-in-class RAS inhibitor for metastatic pancreatic cancerThe U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a RAS inhibitor, for the treatment of metastatic pancreatic adenocarcinoma. Rasonque is a tablet taken once daily that t…
- FDA clears first wearable that continuously tracks both glucose and ketone levelsThe U.S. Food and Drug Administration has authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for individuals aged two years and older who have diabetes. The device is…